$HAE (Haemonetics Corporation)

$HAE {{ '2016-05-09T22:13:01+0000' | timeago}} • Announcement

Healthcare company $HAE said that it has named Christopher Simon as President and Chief Executive Officer of the company effective May 16, 2016. Mr. Simon will succeed Ronald Gelbman, who had been serving as interim Chief Executive Officer since Sept. of 2015.

$INCY {{ '2017-07-20T13:24:37+0000' | timeago}} • Announcement

$INCY said first patient has been treated in Phase 3 trial of itacitinib for the first-line treatment of patients with acute graft-versus-host disease (GVHD). GVHD is a condition that might occur after an allogeneic transplant, whereby the donated bone marrow or peripheral blood stem cells view the recipient’s body as foreign and attack the body.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$TBPH {{ '2017-07-20T12:32:48+0000' | timeago}} • Announcement

$TBPH and $MYL announced positive results from a 12-month Phase 3 safety study of revefenacin in patients with chronic obstructive pulmonary disease (COPD). The study of 1,055 patients with COPD demonstrated that revefenacin was generally well-tolerated, and no new safety issues were identified.

$AKRX {{ '2017-07-19T21:41:28+0000' | timeago}} • Announcement

Specialty generic pharmaceutical company $AKRX said that its shareholders have voted to approve the merger for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA. The companies expect the acquisition to close by early 2018.

$AGN {{ '2017-07-19T15:54:53+0000' | timeago}} • Announcement

$AGN appointed Joseph Boccuzi to its BoD, effective immediately. Boccuzi recently retired as a Partner in the Global Life Sciences, Board and Chief Executive Officer Practices at Spencer Stuart, following 24 years of service with the global executive search and leadership consulting firm.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$PRGO {{ '2017-07-17T13:30:02+0000' | timeago}} • Announcement

$PRGO received final approval from the FDA for its AB rated Abbreviated New Drug Application referencing $ABBV's Androgel Topical Gel, 1.62% packets. The gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$MYL {{ '2017-07-14T12:05:52+0000' | timeago}} • Announcement

Pharma firm $MYL said the FDA Oncologic Drugs Advisory Committee has recommended approval of the biosimilar trastuzumab developed by Mylan along with India-based Biocon Ltd. for  treatment of breast cancer. The committee determined no clinically meaningful differences exist between the biosimilar product and cancer drug Herceptin.

$AMGN {{ '2017-07-13T12:24:26+0000' | timeago}} • Announcement

$AMGN and $AGN announced they will discuss data supporting the ABP 215 Biologics License Application (BLA) with FDA's Oncologic Drugs Advisory Committee. ABP 215 is a biosimilar candidate to Avastin (bevacizumab) and is the first bevacizumab biosimilar candidate to be considered by the FDA.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$AGN {{ '2017-07-10T16:14:16+0000' | timeago}} • Announcement

$AGN announced additional results of a prespecified prospective pooled subgroup analysis from the two Phase 3 studies, which evaluated the efficacy and safety of Viberzi to treat the symptoms associated with irritable bowel syndrome with diarrhea, abdominal pain and diarrhea.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$LIVN {{ '2017-06-29T15:56:55+0000' | timeago}} • Announcement

$LIVN received FDA approval of its VNS Therapy system in patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

$AGN {{ '2017-06-27T13:15:55+0000' | timeago}} • Announcement

Pharma company $AGN launched Refresh Optive Mega-3, an over-the-counter artificial tear under the company’s Refresh portfolio. The formulation protects tears from evaporating while nourishing the damaged lipid layer and providing essential hydration to the tear film layers in patients suffering from ‘dry eye’.

$OSUR {{ '2017-06-27T12:34:45+0000' | timeago}} • Announcement

$OSUR has signed an agreement with Bill & Melinda Gates Foundation, under which the company will offer its OraQuick HIV Self-Test at an affordable price in 50 developing countries with funding from the foundation. The funding will comprise support payments tied to the volume of product sold by OraSure, and reimbursement of certain related costs.

$ABBV {{ '2017-06-23T16:10:50+0000' | timeago}} • Announcement

$ABBV said Maviret, if approved, will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV. The European Commission will now review the CHMP opinion and a final decision is expected in 3Q17.

$ABBV {{ '2017-06-23T16:10:05+0000' | timeago}} • Announcement

$ABBV said the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending marketing authorization of Maviret, an investigational, pan-genotypic treatment for adults with chronic hepatitis C virus (HCV) infection.

Recent Transcripts

ANGO (AngioDynamics Inc.)
Tuesday, July 18 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
MYL (Mylan N.V.)
Wednesday, May 10 2017 - 2:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
AGN (Allergan plc)
Tuesday, May 9 2017 - 12:30pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
INCY (Incyte Corporation)
Thursday, May 4 2017 - 2:00pm
TFX (Teleflex Incorporated)
Thursday, May 4 2017 - 12:00pm
OSUR (OraSure Technologies, Inc.)
Wednesday, May 3 2017 - 9:00pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, May 2 2017 - 9:00pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
EW (Edwards Lifesciences Corp.)
Tuesday, April 25 2017 - 9:00pm
SYK (Stryker Corporation)
Tuesday, April 25 2017 - 8:30pm
NURO (NeuroMetrix Inc.)
Thursday, April 20 2017 - 12:00pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
ANGO (AngioDynamics Inc.)
Thursday, March 30 2017 - 12:00pm
KTWO (K2M Group Holdings, Inc.)
Monday, March 6 2017 - 10:00pm
AKRX (Akorn, Inc.)
Wednesday, March 1 2017 - 3:00pm

AlphaGraphics you may like